Bile Acids, Genetic Control and Ileo-Colonic Mucosal Expression in Irritable Bowel Syndrome-Diarrhea (IBS-D)

Overview

About this study

The purpose of this study is to understand the role of genetics (inherited genes from biological parents) and expression of genes and proteins in the lining of the intestine and colon in the development of diarrhea in patients with irritable bowel syndrome with or without bile acid malabsorption. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion criteria                                        Asymptomatic controls              IBS patients

Age (yr)                                                           18-75                                       18-75

Gender (F:M)                                                   10:1                                         10:1

BDQ - IBS symptoms                                     -ve by Rome III criteria          +ve by Rome III criteria

Hospital Anxiety/Depression score                 <8                                            No restrictions

Abdominal surgery (except appy or choly)     None                                        None

GI medications                                                None past 6 months               None past 48h

 

Exclusion criteria

In all patients diagnosed with IBS, we apply rigorous standards to exclude clinically-relevant inflammation. Patients with known bleeding diathesis will be excluded, given the need for sigmoid mucosal biopsies.  Anyone with a known allergy to Midazolam and Fentanyl for Aim 2 in protocol and named medications.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Camilleri, M.D.

Open for enrollment

Contact information:

Sara Linker Nord CCRP

(507)266-1999

LinkerNord.Sara@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20306541

Mayo Clinic Footer